55 results about "Retina/choroid" patented technology

Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

Featured is a methodology for administering a therapeutic medium to the posterior segment of an eye including instilling or disposing the therapeutic medium sub-retinally. In particular embodiments, the therapeutic medium is disposed in a sub retinal space. Such instillation being accomplished by one of injection or implantation of the therapeutic medium sub-retinally or the sub-retinal space. In other aspects, the methodology further includes forming a limited retinal detachment so as to define the sub-retinal space as well as methods for treating an eye by sub-retinally administering a therapeutic medium.

An illumination system for fundus imaging apparatus employing transcleral illumination of the interior of the eye. Color images of the interior of the eye are obtained by illuminating the sclera successively with red, yellow and green light. Those images are then treated as red, green and blue images by a post processing unit, which combines them to give a color image. This is useful for observing or imaging the interior of the eye, the retina, or the choroid. The observation or the imaging of the interior of the eye, the retina, or the choroid by applying the disclosed illumination method can be performed in conjunction with any system that includes optics for that purpose.

The invention is a retinal implant device to stimulate a retina of an eye thereby producing a specific effect in an eye, such as vision or drug treatment of a chronic condition. The retinal device is made of a retinal implant that is positioned subretinally and that contains a multitude of stimulation sites that are in contact with the retina. A connection carries the stimulating electrical signal or drug. The connection passes transretinally through the retina and into the vitreous cavity of the eye, thereby minimizing damage to the nutrient-rich choroid. The lead is attached to a source of drugs or electrical energy, which is located outside the eye. The lead passes through the sclera at a point near the front of the eye to avoid damage to the retina.

Age-related macular degeneration is treated by radiation delivered from a miniature x-ray tube inserted via a catheter around the globe of the eye, to a position behind the macula. Methods are described for properly locating the catheter and x-ray tube, using illumination on the catheter and viewing through the front of the eye, or sensors on the catheter and a scanned beam shone from the front of the eye. Fluorescent material excited by x-rays can also be used. Also described are methods and devices for immobilizing the probe once properly located in the eye, for standoff of the x-ray tube from the target issue, and for achieving prescription radiation dose in the choroid while eliminating dose to adjacent tissues. The x-ray treatment can be enhanced using a radiosensitizing drug, and can be combined with PDT.

Formulations and methods useful to reduce ocular neovascularization (new blood vessels in the cornea, retina, conjunctiva, and/or choroid) are disclosed. According to the invention the formulation will include tetracycline or a derivative thereof including chemically modified tetracyclines (CMT) which inhibit matrix metalloproteinase (MMP) activity at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye in an amount and for a duration sufficient to reduce ocular neovascularization. According to the invention the formulations are preferably in pharmaceutically acceptable formulations for topical ocular application, ocular injection, or ocular implantation, and may be contained in liposomes or slow release capsules.

A visual restoration aiding device for restoring vision of a patient, comprises: a substrate which will be placed on or under a retina, a choroid or a sclera of a patient's eye; a plurality of electrodes arranged on the substrate for applying electrical stimulation pulse signals to cells constituting the retina; a photographing unit which photographs an object to be recognized by the patient; and a control unit which controls output of the electrical stimulation pulse signals from each electrode based image data captured by the photographing unit. The number of the electrodes placed on the substrate is less than the number of electrodes that can simultaneously output the electrical stimulation pulse signals based on the image data corresponding to one frame. The control unit is configured to sequentially output the electrical stimulation pulse signals at predetermined time interval based on the divided image data corresponding to one frame so as to allow the patient to recognize the image corresponding to one frame by joining two or more divided sections of the image corresponding to one frame.

Discussed is a method and apparatus of correcting retinal detachments by heat-shrinking a specially designed scleral band equipped with a snap-on custom-made buckle for scleral indentation over the retinal tear region. The heat shrink band is made from a heat shrink material such as a polymer or an alloy and is equipped with a custom-made buckle to perfectly fit the topological geometry of the retinal detachment region over the underlying choroid and the sclera, the conjunctiva and within the Tenon's space wherein the band is heat shrunk to create a perfect buckle over the retinal tear region to reattach the retina to the choroid and cause absorption of the subretinal fluid. Conventional, laser, microwave, Joule or radio-frequency (RF) heating means are also discussed.

Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and/or choroid) are illustrated. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise heparin in a concentration and dose suitable for treating ocular neovascularization, characterized in that said compound is at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye. Use of drugs like steroids in the treatment of such ocular neovascularization ailments can increase intraocular pressure (glaucoma).

Although a lamina cribrosa is deformed in glaucoma, in a method in a related art, a thickness of retinal layer or choroid is measured and a deformation of the lamina cribrosa is not detected. When glaucoma is diagnosed, it is desirable to analyze a shape of the lamina cribrosa and present its analysis result at a high visibility. An image processing apparatus is provided that comprises: an image obtaining unit that obtains a tomographic image of a subject's eye; an extracting unit that extracts a lamina cribrosa from the tomographic image; and a display control unit that controls a display means to display a display form showing a shape of the extracted lamina cribrosa.

An object of the present invention is to find a novel medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent inhibitory effect on neovascularization in the choroid and also has a protective effect on retinal pigment epithelial cell damage, and therefore is useful as a prophylactic or therapeutic agent for age-related macular degeneration.

The invention provides an application of puerarin gel eye drop in preparation of drugs for treating ischemic ocular fundus diseases. The eye drop is prepared from puerarin, EDTA, sodium metabisulfite, borneol, benzalkonium bromide, poloxamer 407, sodium hyaluronate, sodium citrate, citric acid and injection water, an HPLC-UV method is adopted, intraocular pharmacokinetics of rabbits proves that the absorbed doses of 1.2% puerarin gel eye drop in retina and choroid are respectively larger than 70% and 62% in common puerarin eye drop; converted according to specific gravity of aqueous fluid and vitreous body, intraocular puerarin contents satisfy the relation that choroid> retina>aqueous fluid > vitreous body, which indicates that an enough absorbed dose of the puerarin can reach ocular fundus. Observation finds that average drug contents (ng/g) of the 1.2% puerarin gel eye drop on time points of a 1-6 hour puerarin time-concentration curve of rabbit retina and choroid are not lower than contents (ng/g) measured when rabbits effectively induce reinforced ocular fundus blood flow velocity in retina hemodynamics measurement, so that the fact that the puerarin gel eye drop can be used as intravenous puerarin for treating ischemic ocular fundus diseases can be proved.

The present inventors administered a peptide derived from VEGFR-2, which is known as one of the proteins involved in neovascularization, to model mice (A2/Kb transgenic mice) expressing human HLA-A*0201, and tested whether or not the peptide has vaccine effect. As a result, the present inventors successfully discovered that vaccination using this peptide as an antigen is effective for inhibition of choroid neovascularization, and thereby completed the present invention. More specifically, the present invention provides vaccines for treatment and/or prevention of diseases caused by choroid neovascularization (neovascular maculopathy), which contain a VEGFR-2-derived peptide as an active ingredient.

The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

The invention discloses a choroid and iris stitching instrument which comprises a rod-shaped handle and a stitching needle fixedly connected with the handle. The stitching needle is in the shape of a solid round rod; the length of the stitching needle is 30-40 mm; the diameter of the stitching needle is 0.5-0.6 mm; and a thread hole is formed in the tip of the stitching instrument. The choroid and iris stitching instrument is simple in structure, quick and easy to operate and suitable for stitching various traumatic choroids and irises. Incisions are small, the needle can enter an eye to stitch under a microscope, and stitching accuracy is guaranteed; in addition, operation steps can be reduced obviously, and operation time is shortened; injury on other tissues is reduced; and technical requirements on doctors are reduced relatively. In a word, a powerful technical support is provided for stitching of choroids and irises, and the choroid and iris stitching instrument has a quite important clinical practical significance.

The invention discloses a choroidal neovascularization growth protection method combining a constitutive model with a finite element. The method comprises the steps of image preprocessing; area division and partition, specifically including dividing an image into four areas consisting of a CNV area, an outer retina layer, an inner retina layer and a choroids layer; meshing, specifically including performing tetrahedral mesh generation on the four areas; modeling, specifically including modeling by using a hyperelastic biomechanical model and a reaction diffusion equation, and adding quality variation after choroidal neovascularization grows into an equation as a source item, thus causing a deformation gradient tensor to continuously change according to the growth of the new vessel; optimizing the model, computing the best accuracy rate, and performing parameter test; and fitting a parameter curve according to a parameter predicted at each time point, and predicting the growth parameter of the last time point to acquire a prediction result. According to the method provided by the invention, the biomechanical model can be built in a more flexible and personalized mode, the model assumes that organization is orthotropic, the good prediction results can be provided for non-linear large-deformation areas, and the accuracy is high.

The invention relates to a method for externally separated preparing retina organism sheath, wherein it comprises 1, preparing gelatin sheet that adding germ-free physiological salt water into gelatin powder, heating, boiling and fusing, cooling in cylinder module, using vibration cutter to cut it into gelation sheets; 2, storing the retina organism sheet that laying the retina adhered with choroids on the surface of gelation sheet while the choroids is upward, to be stored in storage liquid; 3, laser micro cutting the retina sheet that using quasi-molecular laser, using the optical cornea embed mode to emit laser, to cut off the choroids, then packing it with gelation, emerging it in storage liquid. The invention can separate the retina organism from choroids, with integral structure and organism activity.